Muc-1 Expression May Help Characterize Thyroid Nodules but Does Not Predict Patients' Outcome

作者：Morari Elaine Cristina; Silva Joyce Rosario; Trindade Guilhen Ana Carolina; Cunha Lucas Leite; Marcello Marjory Alana; Soares Fernando Augusto; Vassallo Jose; Ward Laura Sterian^*

来源：Endocrine Pathology, 2010, 21(4): 242-249.

DOI：10.1007/s12022-010-9137-4

• MUC1
• Thyroid cancer
• Benign nodules
• Follicular carcinomas
• Follicular adenomas

Our purpose was to evaluate MUC1 clinical utility in the diagnosis and prognosis of thyroid cancer patients. We studied the protein expression of MUC1 in 289 thyroid carcinomas and 121 noncancerous thyroid nodules. There were 41 follicular carcinomas (FC) and 248 papillary thyroid carcinomas (PTC) including 149 classic (CPTC), 20 tall cell (TCPTC) and 79 follicular variants (FVPTC). In addition, we used a quantitative real-time PCR (q-PCR) method to measure MUC1 mRNA expression levels in 108 carcinomas, 23 hyperplasias, and 19 FA. According to their serum Tg levels and other evidences of recurrence/metastasis, the patients were classified as free-of-disease (185 cases) or bad outcome (56 cases, 10 deaths). MUC1 protein was identified in 80.2% PTC; 48.8% FC; 68.3% FVPTC; 70% TCPTC; 21.8% FA; 30% hyperplasias and 6% normal thyroid tissues. MUC1 distinguished benign from malignant thyroid tissues (sensitivity = 89%; specificity = 53%). MUC1 also differentiated FC from FA (p = 0.0083). q-PCR mRNA expression of MUC1 also distinguished malignant from benign nodules (Mann-Whitney test, p < 0.0001). However, neither IHC nor mRNA MUC1 expression was associated with any clinical or pathological feature of aggressiveness or outcome. We suggest that MUC1 expression may help differentiate follicular patterned thyroid lesions.

• 出版日期2010-12